Alchemia Of Australia Finally Set To File For Synthetic Drug Generic
This article was originally published in PharmAsia News
Executive SummaryAustralia's Alchemia is looking for marketing partners now that it has overcome a three-year delay and filed for U.S. approval of its synthetic anti-clotting generic of GlaxoSmithKline's Arixtra (fondaparinux). Alchemia blamed its delay beyond the original 2006 filing target on the complexities involved in synthesizing the drug. The company expects FDA approval and marketing in the second half of this year, with Dr. Reddy's Laboratories already chosen to market the drug in India. (Click here for more
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.